11/12/2008

Introgen Therapeutics announced that it tapped Torreya Partners, a life sciences consultant, to help the company weigh strategic alternatives, including a possible merger or asset sale. The move comes after the FDA declined in September to approve cancer drug Advexin because Introgen's application was incomplete.

Related Summaries